Renovaro BiosciencesNASDAQ: RENB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 February 2018

Next earnings report:

21 November 2024

Last dividends:

N/A

Next dividends:

N/A
$75.11 M
-88%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:02:39 GMT
$0.47-$0.02(-3.84%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RENB Latest News

Renovaro Issues Shareholder Letter and Provides Corporate Update
globenewswire.com04 November 2024 Sentiment: POSITIVE

LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, It is my honor to address you as the newly appointed CEO of Renovaro Inc. After careful consideration, I left a 40-year career on Wall Street to join Renovaro because I believe the Company has tremendous potential in its verticals, such as the dendritic cancer cell vaccine (DCCV) and AI powered multi-cancer early detection screening and therapeutics.

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
globenewswire.com17 October 2024 Sentiment: POSITIVE

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.

Renovaro Announces Strategic Restructuring and Leadership Transition
globenewswire.com16 October 2024 Sentiment: POSITIVE

LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
globenewswire.com13 September 2024 Sentiment: POSITIVE

AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.

RenovaroCube Announces Strategic Offering of Up to 20% Ownership
globenewswire.com11 September 2024 Sentiment: POSITIVE

AMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary.

Renovaro, Inc. Announces $10 million in Equity Committed
globenewswire.com14 June 2024 Sentiment: POSITIVE

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage. “We appreciate confidence in the Company demonstrated by the investors,” said the Hon.

What type of business is Renovaro Biosciences?

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

What sector is Renovaro Biosciences in?

Renovaro Biosciences is in the Healthcare sector

What industry is Renovaro Biosciences in?

Renovaro Biosciences is in the Biotechnology industry

What country is Renovaro Biosciences from?

Renovaro Biosciences is headquartered in United States

When did Renovaro Biosciences go public?

Renovaro Biosciences initial public offering (IPO) was on 07 February 2018

What is Renovaro Biosciences website?

https://renovarobio.com

Is Renovaro Biosciences in the S&P 500?

No, Renovaro Biosciences is not included in the S&P 500 index

Is Renovaro Biosciences in the NASDAQ 100?

No, Renovaro Biosciences is not included in the NASDAQ 100 index

Is Renovaro Biosciences in the Dow Jones?

No, Renovaro Biosciences is not included in the Dow Jones index

When was Renovaro Biosciences the previous earnings report?

No data

When does Renovaro Biosciences earnings report?

The next expected earnings date for Renovaro Biosciences is 21 November 2024